# Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-of-anti-pd-1-antibodies-in-nsclc-patients-with-an-egfr-mutation-and/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Ken Masuda,Hidehito Horinouchi,Midori Tanaka,Ryoko Inaba Higashiyama,Yuki Shinno,Jun Sato,Yuji Matsumoto,Yusuke Okuma,Tatsuya Yoshida,Yasushi Goto,Noboru Yamamoto,Yuichiro Ohe |
| Citations | 93 |
| DOI | 10.1007/s00432-020-03329-0 |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s00432-020-03329-0.pdf |
| OpenAlex ID | https://openalex.org/W3044933172 |
| PMID | 32705363 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Yusuke Okuma](https://scholariq.org/researchers/yusuke-okuma/)
- [Yuji Matsumoto](https://scholariq.org/researchers/yuji-matsumoto/)

## Paper journal

- [Journal of Cancer Research and Clinical Oncology](https://scholariq.org/journals/journal-of-cancer-research-and-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.